Noveris Health Sciences Valuation Multiples

Noveris Health Sciences is valued at $1M as of November 2026. In the last fiscal year, Noveris Health Sciences EBITDA was $2M.

Noveris Health Sciences Overview

About Noveris Health Sciences

Noveris Health Sciences Inc, formerly Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.


Founded

2013

HQ

Canada

Employees

3

Financials (Last FY)

Revenue: -
EBITDA: $2M

EV

$923K

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Noveris Health Sciences Financials

Noveris Health Sciences reported last fiscal year revenue of - and EBITDA of $2M.

In the same fiscal year, Noveris Health Sciences generated $2M in EBITDA and $2M in net income.


Noveris Health Sciences P&L

In the most recent fiscal year, Noveris Health Sciences reported revenue of - and EBITDA of $2M.

Noveris Health Sciences is profitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for Noveris Health Sciences
Last FY2025202620272028
EBITDA$2M$2M
Net Profit$2M$2M
Net Debt$7M-

Financial data powered by Morningstar, Inc.

Noveris Health Sciences Stock Performance

Noveris Health Sciences has current market cap of $1M, and enterprise value of $923K.

Market Cap Evolution


Noveris Health Sciences' stock price is $0.02.

Noveris Health Sciences has an EPS (earnings per share) of $0.03.

See more trading valuation data for Noveris Health Sciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$923K$1M-0.0%---$0.03

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Noveris Health Sciences Valuation Multiples

Noveris Health Sciences trades at 0.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Noveris Health Sciences

Noveris Health Sciences Financial Valuation Multiples

As of November 19, 2026, Noveris Health Sciences has market cap of $1M and EV of $923K.

Noveris Health Sciences has a P/E ratio of 0.6x.

Last FY2025202620272028
EV/EBITDA0.4x0.4x
EV/EBIT(2.4x)(2.4x)
P/E0.6x0.6x
EV/FCF122.6x122.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Noveris Health Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Noveris Health Sciences Operational KPIs

Noveris Health Sciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.1M for the same period.

Access forward-looking KPIs for Noveris Health Sciences
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$0.1M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Noveris Health Sciences Competitors

Noveris Health Sciences competitors include Respiratorius, Gabather, Geovax Labs, Biodexa Pharmaceuticals, Matinas BioPharma Holdings, Avenue Therapeutics, Bone Biologics, Cannovum Cannabis, Clearmind Medicine and PMGC Holdings.

Most Noveris Health Sciences public comparables operate across Nutraceuticals & Cosmeceuticals, Biopharmaceuticals and BioTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Respiratorius-($350K)--(3.2x)-
Gabather-($446K)--(1.7x)(1.6x)
Geovax Labs$2M($22M)----
Biodexa Pharmaceuticals-($8M)----
Matinas BioPharma Holdings-($10M)--(0.0x)-
Avenue Therapeutics$1M($3M)----
Bone Biologics-($3M)----
Cannovum Cannabis-($447K)--(2.1x)-

This data is available for Pro users. Sign up to see all Noveris Health Sciences competitors and their valuation data.

Start Free Trial

Acquisitions by Noveris Health Sciences

Noveris Health Sciences has acquired 1 company to date.

Last acquisition by Noveris Health Sciences was on June 10th 2020. Noveris Health Sciences acquired NeuroPharm for $6M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Noveris Health Sciences

NeuroPharm
Description
NeuroPharm was a Vancouver-based company developing evidence-based psychedelic-based therapies. Mydecine Innovations Group acquired it in an all-stock transaction that closed in 2020.
HQ CountryCanada
HQ City
Vancouver
Deal Date10 Jun 2020
Valuation$6M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Noveris Health Sciences acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Noveris Health Sciences

When was Noveris Health Sciences founded?Noveris Health Sciences was founded in 2013.
Where is Noveris Health Sciences headquartered?Noveris Health Sciences is headquartered in Canada.
How many employees does Noveris Health Sciences have?As of today, Noveris Health Sciences has over 3 employees.
Is Noveris Health Sciences publicly listed?Yes, Noveris Health Sciences is a public company listed on Canadian Securities Exchange.
What is the stock symbol of Noveris Health Sciences?Noveris Health Sciences trades under NVRS ticker.
When did Noveris Health Sciences go public?Noveris Health Sciences went public in 2014.
Who are competitors of Noveris Health Sciences?Noveris Health Sciences main competitors include Respiratorius, Gabather, Geovax Labs, Biodexa Pharmaceuticals, Matinas BioPharma Holdings, Avenue Therapeutics, Bone Biologics, Cannovum Cannabis, Clearmind Medicine, PMGC Holdings.
What is the current market cap of Noveris Health Sciences?Noveris Health Sciences' current market cap is $1M.
Is Noveris Health Sciences profitable?No, Noveris Health Sciences is not profitable.
How many companies Noveris Health Sciences has acquired to date?As of November 2026, Noveris Health Sciences has acquired 1 company.
What was the largest acquisition by Noveris Health Sciences?$6M acquisition of NeuroPharm on 10th June 2020 was the largest M&A Noveris Health Sciences has done to date.
What companies Noveris Health Sciences acquired?Noveris Health Sciences acquired NeuroPharm.
In how many companies Noveris Health Sciences has invested to date?Noveris Health Sciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Noveris Health Sciences

Lists including Noveris Health Sciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial